NVCT · Nuvectis Pharma, Inc.
$23.56
+0.21 (+0.90%)
At close · Aug 21
Market Cap
$767.62M
Shares
32.58M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-08-21 | 2026-07-20 | |
| 8-K | 2026-08-04 | — | |
| 10-Q | 2026-08-04 | 2026-06-30 | |
| 8-K | 2026-06-30 | 2026-06-29 | |
| 8-K | 2026-06-29 | — | |
| 8-K | 2026-06-23 | 2026-06-22 | |
| Investor Event Transcript | 2026-06-22 | 2026-06-30 | |
| 8-K | 2026-06-12 | 2026-06-11 | |
| Investor Event Transcript | 2026-05-19 | 2026-06-30 | |
| 10-Q | 2026-05-05 | 2026-03-31 | |
| 8-K | 2026-05-05 | — | |
| DEF 14A | 2026-04-27 | 2026-06-11 | |
| 10-K | 2026-02-11 | 2025-12-31 | |
| 8-K | 2026-02-11 | — | |
| 10-Q | 2025-11-04 | 2025-09-30 | |
| 8-K | 2025-11-04 | — | |
| 8-K | 2025-09-25 | 2025-09-22 | |
| 8-K | 2025-08-05 | — | |
| 10-Q | 2025-08-05 | 2025-06-30 | |
| 8-K | 2025-06-13 | 2025-06-12 | |
| 8-K | 2025-05-09 | — | |
| 8-K | 2025-05-06 | — | |
| 10-Q | 2025-05-06 | 2025-03-31 | |
| DEF 14A | 2025-04-28 | 2025-06-12 | |
| 8-K | 2025-02-25 | — | |
| 10-K | 2025-02-25 | 2024-12-31 | |
| 8-K | 2025-02-06 | 2025-02-05 | |
| 8-K | 2024-11-05 | — | |
| 10-Q | 2024-11-05 | 2024-09-30 | |
| 8-K | 2024-08-29 | — | |
| 8-K | 2024-08-06 | — | |
| 10-Q | 2024-08-06 | 2024-06-30 | |
| 8-K | 2024-06-13 | — | |
| 8-K | 2024-05-07 | — | |
| 10-Q | 2024-05-07 | 2024-03-31 | |
| DEF 14A | 2024-04-29 | 2024-06-13 | |
| 10-K | 2024-03-05 | 2023-12-31 | |
| 8-K | 2024-03-05 | — | |
| 8-K | 2023-11-08 | — | |
| 10-Q | 2023-11-08 | 2023-09-30 | |
| 8-K | 2023-09-12 | — | |
| 8-K | 2023-08-17 | — | |
| 8-K | 2023-08-09 | — | |
| 10-Q | 2023-08-09 | 2023-06-30 | |
| 8-K | 2023-07-03 | 2023-06-30 | |
| 8-K | 2023-06-16 | — | |
| 8-K | 2023-05-15 | — | |
| 10-Q | 2023-05-10 | 2023-03-31 | |
| 8-K | 2023-05-10 | — | |
| DEF 14A | 2023-04-28 | 2023-06-16 |
Showing 1–50 of 63 filings
Key facts
CIK
1875558
CUSIP
67080T108
13F (30d)
76 filings
76 filers
Visit website
Investor relations